期刊文献+

抗肿瘤血管生成研究的现状与有待解决的问题 被引量:1

Present studies on anti-tumor angiogenesis and the problems to be resolved
下载PDF
导出
摘要   血管生成是指在原有组织血管结构基础上形成新血管结构的过程.1971年Folkmant[1]提出了肿瘤血管依赖性生长的概念,并把肿瘤生长分为非血管期和血管期两个生长阶段.固体肿瘤在血管生成前,肿瘤体积一般不超过3 mm3.随着肿瘤细胞的不断增殖,肿瘤组织出现缺氧、代谢产物堆积、pH值改变等,这些因素刺激肿瘤细胞、周围间质细胞和淋巴细胞分泌各种促血管生长刺激因子,通过诱导血管基底膜降解和内皮细胞增殖,启动新生血管的生成.……
出处 《中国医药生物技术》 CSCD 2007年第3期162-165,共4页 Chinese Medicinal Biotechnology
  • 相关文献

参考文献2

二级参考文献12

  • 1FolkmanJ.Clinicalapplicationofresearchonantiangiogenesis[].The New England Journal of Medicine.1995
  • 2O’ReillyMS,BoehmT,ShingY etal.Endostatin:anendogenousinhibitorofangiogenesisandtumorgrowth[].Cell.1996
  • 3BlezingerP,WangJJ,GoneoM etal.Systemicinhibitionoftumorgrowthandtumormetastasesbyintramuscularadministrationoftheendostatin gene[].Nature Biotechnology.1999
  • 4LiL,WuPH,LiuRY etal.Inhibitioneffectsofrecombinantadenovirus mediatedhumanendostatin genetherapyonthegrowthofhumanhepatocellularcarcinomaxenograftinnudemice[].ChinJHepatol.2003
  • 5HuangW,FlintSJ.Unusual propertiesofadenovirusE2EtranscriptionbyRNApolymeraseIII[].Journal of Virology.2003
  • 6HanhanD,FolkmanJ.Patternsandemergingmechanismoftheangiogenicswitchduringtumorigenesis[].Cell.1996
  • 7HahnfeldtP,PanigraphyD,FolkmanJ etal.Tumordevelopmentunderangiogenicsignaling:adynamictheoryoftumorgrowth treatmentresponse andpostvasculardormancy[].Cancer Research.1999
  • 8BoehmT,PirieShepherdS,TrinhLB etal.DisruptionoftheKEX1geneinPichia pastorisallowsexpressionoffull lengthmurineandhumanendostatin[].Yeast.1999
  • 9FeldmanAL,RestifoNP,AlxenderDL etal.Antiangiogenicgenetherapyofutilizingarecombinantadenovirustoelevatesystemicendostatinlevelinmice[].Cancer Research.2000
  • 10Szary J,Szala S.Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth[].International Journal of Cancer.2001

共引文献17

同被引文献23

  • 1翟鑫,王玉亚,宫平.以血管内皮生长因子及其受体为靶点的肿瘤血管生成抑制剂的研究进展[J].中国药物化学杂志,2006,16(1):60-64. 被引量:7
  • 2陈川(综述),俞德超(审阅),滕理送(审阅).以VEGF/VEGFR为靶点的抗肿瘤药物的研究进展[J].中国肿瘤生物治疗杂志,2007,14(3):291-295. 被引量:25
  • 3Pradeep CR, Sunila ES, Kuttan G. Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies[J]. Integrative Cancer Therapies, 2005, 4(4):315-321.
  • 4Patficia A, Burke, Sally J, et al. Antiangiogenic agents and their promising potential in combined therapy [J]. Critical Reviews in Oncology/Hematology, 2001, 39(1-2):155-171.
  • 5Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer [J]. Oneogene, 2003, 22:6549-6556.
  • 6Folkman J. Tumor angiogenesis: therapeutic implications [J]. N Engl J Med 1971, 285:1182-1186.
  • 7Safran M, Kaelin WJ. HIF hydroxylation and the mammalian oxygen-sensing pathway [J]. J. Clin. Invest, 2003, 111(6):779-783.
  • 8Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors [J].Nature Med, 2003, 9(6):669-676.
  • 9Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab [J]. Angiogenesis, 2012, 15(2):171-185.
  • 10Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression [J]. Critical Reviews in Oncology/Hematology, 2007, 62:179-213.

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部